Researchers examined trends in adherence to various treatment among patients with psoriasis using data from a large health insurance database. For which therapy had the highest odds for adherence, read more.

FDA Alerts

FDA Alerts
Monday, April 25, 2016
Ixekizumab (Taltz, Eli Lilly and Company) received FDA approval as a new treatment for moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy or a combination of both therapies.
FDA Alerts
Wednesday, March 23, 2016
Ixekizumab (Taltz, Eli Lilly and Company) received FDA approval as a new treatment for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy, or a combination of both therapies.
FDA Alerts
Monday, February 8, 2016
A new prescription topical steroid has received FDA approval for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. Betamethasone dipropionate (Sernivo) Spray, 0.05%, from Promius Pharma, LLC, US, a subsidiary of Dr. Reddy’s, will be available next quarter.
FDA Alerts
Saturday, January 16, 2016
The FDA recently approved secukinumab (Cosentyx) for 2 new indications for the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA).

News

News
Friday, December 22, 2017
Psoriasis is commonly treated by targeting Th17 cells and interleukin 17 cytokines. Although atopic dermatitis is often treated differently, certain subtypes of atopic dermatitis may benefit from certain aspects of psoriasis treatment.
News
Wednesday, December 20, 2017
Although previous studies have shown an association between psoriasis and insulin resistance characteristic for type 2 diabetes, little is currently known about how this condition affects the clinical course of type 1 diabetes.
News
Friday, December 15, 2017
Health care utilization in the United States often differs by race and ethnicity. However, less data currently exists about whether health care utilization for skin diseases in particular differs by race.
News
Friday, December 8, 2017
Skin conditions such as psoriasis occur more often in individuals who are overweight or obese compared with people who are healthy. In a recent study, researchers aimed to determine whether the severity of psoriasis is affected by body mass index.

NPF Endorsed Articles

NPF Endorsed Articles
Wednesday, March 18, 2015
A new independent US psoriasis registry — a joint collaboration with the National Psoriasis Foundation and Corrona, LLC — will allow people with psoriasis and their healthcare providers to participate in research that aims to improve treatments and disease outcomes.
NPF Endorsed Articles
Tuesday, February 24, 2015
Phototherapy is a safe and effective treatment option for psoriasis. Clinicians should consider phototherapy as a first-line treatment for many patients as well as adjunctive therapy for those who fail to respond to other treatment modalities.  
NPF Endorsed Articles
Tuesday, February 3, 2015
Safe and effective long-term therapy is important when treating patients with psoriasis and maintaining remission of this condition.
NPF Endorsed Articles
Wednesday, January 28, 2015
This article provides several concrete suggestions to help clinicians and patients to enhance their emotional well-being and clinical outcomes.

Research in Review

Research in Review
Wednesday, August 10, 2016
A 42-year-old woman with psoriasis presented for evaluation of a new-onset rash of 1 to 2 weeks’ duration on her trunk and extremities.
Research in Review
Monday, July 25, 2016
Getting patients to take medication as prescribed is essential to getting optimal clinical responses.
Research in Review
Thursday, June 16, 2016
Research shows that psoriasis is much more than a skin condition.